Pulmonary hypertension in patients with chronic and end-stage kidney disease

Kidney International

Volumn 84, Issue 4, 2013, Pages 682-692

  Sise, Meghan E ^a   Courtwright, Andrew M ^b   Channick, Richard N ^b  

^a Department of Medicine   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

cardiovascular disease; chronic kidney disease; echocardiography; ESRD; left ventricular hypertrophy; pulmonary

Indexed keywords

AMBRISENTAN; ANTIANEMIC AGENT; BOSENTAN; CYCLIC GUANOSINE MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ENZYME INHIBITOR; HEMOGLOBIN; ILOPROST; LETARIS; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; REVTIO; SILDENAFIL; TADALAFIL; THROMBOXANE; TREPROSTINIL; UNCLASSIFIED DRUG; VENTAVIST;

ARTERIOVENOUS FISTULA; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG EFFICACY; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDURANCE TRAINING; ERECTILE DYSFUNCTION; FLUSHING; GRAFT RECIPIENT; HEADACHE; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART OUTPUT; HEMODIALYSIS; HEMODYNAMICS; HOSPITALIZATION; HUMAN; HYPOXIA; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; KINESIOTHERAPY; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG BLOOD VESSEL; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; OXYGEN SATURATION; OXYGEN THERAPY; PATHOGENESIS; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RENAL REPLACEMENT THERAPY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOEMBOLISM; TREATMENT OUTCOME; UREMIA; WALKING; WORLD HEALTH ORGANIZATION;

CARDIAC OUTPUT; ENDOTHELIUM, VASCULAR; HEART; HUMANS; HYPERTENSION, PULMONARY; KIDNEY FAILURE, CHRONIC; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84885299623     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.186     Document Type: Review

References (114)

1. Rubin LJ. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 1995; 75: 51A-54A.
2. Yigla M, Fruchter O, Aharonson D et al. Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients. Kidney Int 2009; 75: 969-975.
3. Ataga KI, Moore CG, Jones S et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 2006; 134: 109-115.
4. Proudman SM, Stevens WM, Sahhar J et al. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007; 37: 485-494.
5. Dallari R, Barozzi G, Pinelli G et al. Predictors of survival in subjects with chronic obstructive pulmonary disease treated with long-term oxygen therapy. Respiration 1994; 61: 8-13.
6. Rosenkranz S. Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 2007; 96: 527-541.
7. Badesch DB, Champion HC, Sanchez MA et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S55-S66.
8. Berger M, Haimowitz A, Van Tosh A et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985; 6: 359-365.
9. Sicari R, Gargani L, Wiecek A et al. The use of echocardiography in observational clinical trials: the EURECA-m registry. Nephrol Dial Transplant 2012; 28: 19-23.
10. Fisher MR, Forfia PR, Chamera E et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615-621.
11. McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
12. Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
13. Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol 2005; 98: 390-403.
14. Vender RL. Chronic hypoxic pulmonary hypertension. Cell biology to pathophysiology. Chest 1994; 106: 236-243.
15. Sharma J, Mongia A, Schoenaman M et al. Nephrogenic fibrosing dermatopathy, cardiac calcification and pulmonary hypertension in an adolescent on chronic hemodialysis. Indian J Nephrol 2008; 18: 70-73.
16. Haddad F, Fuh E, Peterson T et al. Incidence, correlates, and consequences of acute kidney injury in patients with pulmonary arterial hypertension hospitalized with acute right-side heart failure. J Card Fail 2011; 17: 533-539.
17. Tatsukawa H, Nagano S, Umeno Y et al. A case of primary Sjogren's syndrome with severe pulmonary hypertension and glomerular damage. Ryumachi 2003; 43: 564-568.
18. Yamaguchi T, Ohshima S, Tanaka T et al. Renal crisis due to intimal hyperplasia in a patient with mixed connective tissue disease (MCTD) accompanied by pulmonary hypertension. Intern Med 2001; 40: 1250-1253.
19. Andersen GN, Vasko J. Scleroderma renal crisis and concurrent isolated pulmonary hypertension in mixed connective tissue disease and overlap syndrome: report of two cases. Clin Rheumatol 2002; 21: 164-169.
20. Yasuda T, Tanabe N, Konishi K et al. Pulmonary hypertension in a patient on chronic hemodialysis. Nihon Kokyuki Gakkai Zasshi 2009; 47: 52-56.
21. Gunduz OH, Fertig N, Lucas M et al. Systemic sclerosis with renal crisis and pulmonary hypertension: a report of eleven cases. Arthritis Rheum 2001; 44: 1663-1666.
22. Cheung AK, Sarnak MJ, Yan G et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65: 2380-2389.
23. Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001; 38: 992-1000.
24. Terzano C, Conti V, Di Stefano F et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung 2010; 188: 321-329.
25. Kraus MA, Hamburger RJ. Sleep apnea in renal failure. Adv Perit Dial 1997; 13: 88-92.
26. Young T, Palta M, Dempsey J et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230-1235.
27. Kumar G, Sakhuja A, Taneja A et al. Pulmonary embolism in patients with CKD and ESRD. Clin J Am Soc Nephrol 2012; 7: 1584-1590.
28. Yigla M, Dabbah S, Azzam ZS et al. Background diseases in 671 patients with moderate to severe pulmonary hypertension. Isr Med Assoc J 2000; 2: 684-689.
29. Etemadi J, Zolfaghari H, Firoozi R et al. Unexplained pulmonary hypertension in peritoneal dialysis and hemodialysis patients. Rev Port Pneumol 2011; 18: 10-14.
30. Yigla M, Nakhoul F, Sabag A et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003; 123: 1577-1582.
31. Yigla M, Keidar Z, Safadi I et al. Pulmonary calcification in hemodialysis patients: correlation with pulmonary artery pressure values. Kidney Int 2004; 66: 806-810.
32. Nakhoul F, Yigla M, Gilman R et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 2005; 20: 1686-1692.
33. Acarturk G, Albayrak R, Melek M et al. The relationship between arteriovenous fistula blood flow rate and pulmonary artery pressure in hemodialysis patients. Int Urol Nephrol 2008; 40: 509-513.
34. Tarrass F, Benjelloun M, Medkouri G et al. Doppler echocardiograph evaluation of pulmonary hypertension in patients undergoing hemodialysis. Hemodial Int 2006; 10: 356-359.
35. Amin M, Fawzy A, Hamid MA et al. Pulmonary hypertension in patients with chronic renal failure: role of parathyroid hormone and pulmonary artery calcifications. Chest 2003; 124: 2093-2097.
36. Mahdavi-Mazdeh M, Alijavad-Mousavi S, Yahyazadeh H et al. Pulmonary hypertension in hemodialysis patients. Saudi J Kidney Dis Transpl 2008; 19: 189-193.
37. Abdelwhab S, Elshinnawy S. Pulmonary hypertension in chronic renal failure patients. Am J Nephrol 2008; 28: 990-997.
38. Paneni F, Gregori M, Ciavarella GM et al. Relation between right and left ventricular function in patients undergoing chronic dialysis. J Cardiovasc Med (Hagerstown) 2013; 14: 289-295.
39. Havlucu Y, Kursat S, Ekmekci C et al. Pulmonary hypertension in patients with chronic renal failure. Respiration 2007; 74: 503-510.
40. Fabbian F, Cantelli S, Molino C et al. Pulmonary hypertension in dialysis patients: a cross-sectional italian study. Int J Nephrol 2011; 2011: 283475.
41. Mousavi SA, Mahdavi-Mazdeh M, Yahyazadeh H et al. Pulmonary hypertension and predisposing factors in patients receiving hemodialysis. Iran J Kidney Dis 2008; 2: 29-33.
42. Issa N, Krowka MJ, Griffin MD et al. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation 2008; 86: 1384-1388.
43. Agarwal R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Transplant 2012; 27: 3908-3914.
44. Ramasubbu K, Deswal A, Herdejurgen C et al. A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. Int J Gen Med 2010; 3: 279-286.
45. Said K, Hassan M, Baligh E et al. Ventricular function in patients with end-stage renal disease starting dialysis therapy: a tissue doppler imaging study. Echocardiography 2012; 29: 1054-1059.
46. Bozbas SS, Akcay S, Altin C et al. Pulmonary hypertension in patients with end-stage renal disease undergoing renal transplantation. Transplant Proc 2009; 41: 2753-2756.
47. Unal A, Sipahioglu M, Oguz F et al. Pulmonary hypertension in peritoneal dialysis patients: prevalence and risk factors. Perit Dial Int 2009; 29: 191-198.
48. Kumbar L, Fein PA, Rafiq MA et al. Pulmonary hypertension in peritoneal dialysis patients. Adv Perit Dial 2007; 23: 127-131.
49. Paneni F, Gregori M, Ciavarella GM et al. Right ventricular dysfunction in patients with end-stage renal disease. Am J Nephrol 2010; 32: 432-438.
50. Papakrivopoulou E, Booth J, Pinney J et al. Comparison of volume status in asymptomatic haemodialysis and peritoneal dialysis outpatients. Nephron Extra 2012; 2: 48-54.
51. Pabst S, Hammerstingl C, Hundt F et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-Study. PLoS One 2012; 7: e35310.
52. Abassi Z, Nakhoul F, Khankin E et al. Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Curr Opin Nephrol Hypertens 2006; 15: 353-360.
53. Thambyrajah J, Landray MJ, McGlynn FJ et al. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000; 83: 205-209.
54. van Guldener C, Lambert J, Janssen MJ et al. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant 1997; 12(Suppl 2): 14-18.
55. Brooks DP. Role of endothelin in renal function and dysfunction. Clin Exp Pharmacol Physiol 1996; 23: 345-348.
56. Vallance P, Leone A, Calver A et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
57. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000; 58: 1261-1266.
58. Schwedhelm E, Boger RH. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol 2011; 7: 275-285.
59. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006; 17: 943-955.
60. Vallance P, Leone A, Calver A et al. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20(Suppl 12): S60-S62.
61. Lilitkarntakul P, Dhaun N, Melville V et al. Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity. Atherosclerosis 2011; 216: 217-225.
62. Mahiout A, Jorres A, Hiss R et al. Effects of blood-dialyser interaction on prostaglandins in uraemic patients and in healthy man. Nephrol Dial Transplant 1987; 2: 546-550.
63. Schmidt RJ, Yokota S, Tracy TS et al. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol 1999; 276: F794-F797.
64. Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 2001; 38: S74-S79.
65. Akmal M, Barndt RR, Ansari AN et al. Excess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy. Kidney Int 1995; 47: 158-163.
66. Yigla M, Abassi Z, Reisner SA et al. Pulmonary hypertension in hemodialysis patients: an unrecognized threat. Semin Dial 2006; 19: 353-357.
67. Grebenyuk LA, Marcus RJ, Nahum E et al. Pulmonary embolism following successful thrombectomy of an arteriovenous dialysis fistula. J Vasc Access 2009; 10: 59-61.
68. Harp RJ, Stavropoulos SW, Wasserstein AG et al. Pulmonary hypertension among end-stage renal failure patients following hemodialysis access thrombectomy. Cardiovasc Intervent Radiol 2005; 28: 17-22.
69. Barak M, Katz Y. Microbubbles: pathophysiology and clinical implications. Chest 2005; 128: 2918-2932.
70. Young PR Jr., Rohr MS, Marterre WF Jr. High-output cardiac failure secondary to a brachiocephalic arteriovenous hemodialysis fistula: two cases. Am Surg 1998; 64: 239-241.
71. Yigla M, Banderski R, Azzam ZS et al. Arterio-venous access in end-stage renal disease patients and pulmonary hypertension. Ther Adv Respir Dis 2008; 2: 49-53.
72. Unal A, Tasdemir K, Oymak S et al. The long-term effects of arteriovenous fistula creation on the development of pulmonary hypertension in hemodialysis patients. Hemodial Int 2010; 14: 398-402.
73. Beigi AA, Sadeghi AM, Khosravi AR et al. Effects of the arteriovenous fistula on pulmonary artery pressure and cardiac output in patients with chronic renal failure. J Vasc Access 2009; 10: 160-166.
74. Clarkson MR, Giblin L, Brown A et al. Reversal of pulmonary hypertension after ligation of a brachiocephalic arteriovenous fistula. Am J Kidney Dis 2002; 40: E8.
75. Buemi M, Senatore M, Gallo GC et al. Pulmonary hypertension and erythropoietin. Kidney Blood Press Res 2007; 30: 248-252.
76. Allegra A, Giacobbe MS, Corvaia E et al. Possible role of erythropoietin in the pathogenesis of chronic cor pulmonale. Nephrol Dial Transplant 2005; 20: 2866-2867.
77. Satoh K, Kagaya Y, Nakano M et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006; 113: 1442-1450.
78. Hasegawa J, Wagner KF, Karp D et al. Altered pulmonary vascular reactivity in mice with excessive erythrocytosis. Am J Respir Crit Care Med 2004; 169: 829-835.
79. Silverberg D, Wexler D, Blum M et al. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004; 13: 163-170.
80. Fathi R, Isbel N, Haluska B et al. Correlates of subclinical left ventricular dysfunction in ESRD. Am J Kidney Dis 2003; 41: 1016-1025.
81. Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344: 102-107.
82. Zlotnick DM, Axelrod DA, Chobanian MC et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant 2010; 25: 3090-3096.
83. Cosio FG, Alamir A, Yim S et al. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int 1998; 53: 767-772.
84. Alekseevskikh IuG, Kolybin VS. [Morphology of the lesser circulation during programmed hemodialysis and the transplantation of a human cadaveric kidney]. Arkh Patol 1988; 50: 60-66.
85. Casas-Aparicio G, Castillo-Martinez L, Orea-Tejeda A et al. The effect of successful kidney transplantation on ventricular dysfunction and pulmonary hypertension. Transplant Proc 2010; 42: 3524-3528.
86. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681-686.
87. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93: 391-398.
88. Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
89. Schrier RW, Bansal S. Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure? Clin J Am Soc Nephrol 2008; 3: 1232-1237.
90. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006; 28: 999-1004.
91. Mereles D, Ehlken N, Kreuscher S et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114: 1482-1489.
92. Stolz D, Rasch H, Linka A et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32: 619-628.
93. Califf RM, Adams KF, McKenna WJ et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54.
94. Packer M, McMurray J, Massie BM et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005; 11: 12-20.
95. Blanco I, Gimeno E, Munoz PA et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181: 270-278.
96. Barst RJ, Gibbs JS, Ghofrani HA et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78-S84.
97. Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
98. Galie N, Brundage BH, Ghofrani HA et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
99. Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2006; CD004434.
100. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
101. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
102. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-434.
103. Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804.
104. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
105. Channick R, Badesch DB, Tapson VF et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 2001; 20: 262-263.
106. Dingemanse J, van Giersbergen PL. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int J Clin Pharmacol Ther 2002; 40: 310-316.
107. Liefeldt L, van Giersbergen PL, Dingemanse J et al. Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. Am J Kidney Dis 2004; 43: 923-926.
108. Dhaun N, MacIntyre IM, Kerr D et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011; 57: 772-779.
109. Dhaun N, Melville V, Blackwell S et al. Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J Am Soc Nephrol 2013; 24: 31-36.
110. Chen J, Mabjeesh NJ, Greenstein A et al. Clinical efficacy of sildenafil in patients on chronic dialysis. J Urol 2001; 165: 819-821.
111. YenicerioGlu Y, Kefi A, Aslan G et al. Efficacy and safety of sildenafil for treating erectile dysfunction in patients on dialysis. BJU Int 2002; 90: 442-445.
112. Kalantar-Zadeh K, Regidor DL, Kovesdy CP et al. Fluid retention is associated with cardiovascular mortality in patients undergoing longterm hemodialysis. Circulation 2009; 119: 671-679.
113. Wizemann V, Wabel P, Chamney P et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 1574-1579.
114. Bolignano D, Rastelli S, Agarwal R et al. Pulmonary Hypertension in CKD. Am J Kidney Dis 2013; 61: 612-622.